CTIC Share Price

Open 0.48 Change Price %
High 0.52 1 Day 0.07 17.50
Low 0.45 1 Week 0.09 23.68
Close 0.47 1 Month 0.14 42.42
Volume 8438359 1 Year -0.64 -57.66
52 Week High 1.22
52 Week Low 0.28
CTIC Important Levels
Resistance 2 0.53
Resistance 1 0.51
Pivot 0.48
Support 1 0.43
Support 2 0.41
BIT Italy Most Active Stocks
PMI 0.31 -3.12%
PMI 0.31 -3.12%
ISP 2.13 -0.47%
TIT 0.72 1.41%
UCG 2.08 0.00%
SPM 0.42 -4.55%
SPM 0.42 -4.55%
ENEL 3.83 1.06%
BP 1.99 -0.50%
BP 1.99 -0.50%
More..
BIT Italy Top Gainers Stocks
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
PGR 300.00 20.00%
CTIC 0.47 17.50%
CTIC 0.47 17.50%
MIC 4.31 7.75%
MIC 4.31 7.75%
MIC 4.31 7.75%
MIC 4.31 7.75%
More..
BIT Italy Top Losers Stocks
PR 0.04 -20.00%
PR 0.04 -20.00%
STEF 0.09 -10.00%
IIN 0.11 -8.33%
IIN 0.11 -8.33%
IIN 0.11 -8.33%
RIC 0.15 -6.25%
RIC 0.15 -6.25%
RIC 0.15 -6.25%
RIC 0.15 -6.25%
More..

Cell Therapeutics, Inc. (BIT: CTIC)

CTIC Technical Analysis 4
As on 2nd Dec 2016 CTIC Share Price closed @ 0.47 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.45 & Strong Buy for SHORT-TERM with Stoploss of 0.36 we also expect STOCK to react on Following IMPORTANT LEVELS.
CTIC Target for December
1st Target up-side 0.47
2nd Target up-side 0.51
3rd Target up-side 0.56
1st Target down-side 0.33
2nd Target down-side 0.29
3rd Target down-side 0.24
CTIC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.celltherapeutics.com
CTIC Address
CTIC
3101 Western Avenue
Suite 600
Seattle, WA 98121
United States
Phone: 206-282-7100
Fax: 206-284-6206
Interactive Technical Analysis Chart Cell Therapeutics, Inc. ( CTIC BIT Italy )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cell Therapeutics, Inc.
CTIC Business Profile
Cell Therapeutics, Inc., a biopharmaceutical company, is engaged in the acquisition, development, and commercialization of treatments for cancer. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione derivative, which is in phase III clinical trials for the treatment of multiply relapsed or refractory aggressive non-Hodgkin lymphoma in the European Union. The company is also developing Pacritinib, an oral inhibitor of Janus Kinase 2 and FMS-like tyrosine kinase, which is in phase III clinical trials for the treatment of myelofibrosis; and is in phase II clinical trial for treatment of relapsed acute myeloid leukemia. In addition, it is developing Tosedostat, an oral aminopeptidase inhibitor that is in phase II clinical trials for the treatment of acute myeloid leukemia; and is in phase II clinical trials for the treatment of acute myeloid leukemia/myelodysplastic syndrome. Further, the company is developing Opaxio, a chemotherapeutic agent that is in phase III clinical trials for the treatment of ovarian cancer; in phase II clinical trials for the treatment of malignant brain cancer; and is in phase II clinical trials for the treatment of head and neck cancer. Additionally, it is developing Brostallicin, which is in phase II clinical trials for the treatment of triple-negative breast cancer. The company has a license and co-development agreement with Chroma Therapeutics, Ltd. to develop and commercialize Tosedostat in North, Central, and South America, or the licensed territory; and a development, commercialization, and license agreement with Baxter International Inc., Baxter Healthcare Corporation, and Baxter Healthcare SA to develop and commercialize Pacritinib worldwide. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.